Label: TOBRAMYCIN solution

  • Category: HUMAN PRESCRIPTION DRUG LABEL

Drug Label Information

Updated May 29, 2020

If you are a healthcare professional or from the pharmaceutical industry please visit this version.

  • DESCRIPTION

    Tobramycin ophthalmic solution, USP 0.3% is a sterile topical ophthalmic antibiotic formulation prepared specifically for topical therapy of external ophthalmic infections.

    Each mL of tobramycin ophthalmic solution, USP 0.3% contains: Active: tobramycin 0.3% (3 mg). Preservative: benzalkonium chloride 0.01% (0.1 mg). Inactives: boric acid, sodium sulfate, sodium chloride, tyloxapol, sodium hydroxide and/or sulfuric acid (to adjust pH) and purified water. Tobramycin ophthalmic solution, USP 0.3% has a pH range between 7.0 and 8.0 and an osmolality of 260-320 mOsm/kg.

    Tobramycin is a water-soluble aminoglycoside antibiotic active against a wide variety of gram-negative and gram-positive ophthalmic pathogens.

    The chemical structure of tobramycin is:

    chemical

    MW=467.52

    Molecular Formula:C18H37N5O9

    Chemical Name: 0-{3-amino-3-deoxy-α-D-gluco-pyranosyl-(1→4)} -0- {2,6-diamino-2,3,6-trideoxy-α-D-ribohexopyranosyl-(1→6) }-2-deoxystreptamine.

  • CLINICAL PHARMACOLOGY

    In Vitro Data

    In vitro studies have demonstrated tobramycin is active against susceptible strains of the following microorganisms: Staphylococci, including S. aureus and S. epidermidis (coagulase-positive and coagulase-negative), including penicillin-resistant strains.

    Streptococci, including some of the Group A-beta-hemolytic species, some nonhemolytic species, and some Streptococcus pneumoniae.

    Pseudomonas aeruginosa, Escherichia coli, Klebsiella pneumoniae, Enterobacter aerogenes, Proteus mirabilis, Morganella morganii, most Proteus vulgaris strains, Haemophilus influenzae and H. aegyptius, Moraxella lacunata, Acinetobacter calcoaceticus and some Neisseria species. Bacterial susceptibility studies demonstrate that in some cases, microorganisms resistant to gentamicin retain susceptibility to tobramycin.

  • INDICATIONS AND USAGE

    Tobramycin ophthalmic solution, USP 0.3% is a topical antibiotic indicated in the treatment of external infections of the eye and its adnexa caused by susceptible bacteria. Appropriate monitoring of bacterial response to topical antibiotic therapy should accompany the use of tobramycin ophthalmic solution, USP 0.3%. Clinical studies have shown tobramycin to be safe and effective for use in children.

  • CONTRAINDICATIONS

    Tobramycin ophthalmic solution, USP 0.3% is contraindicated in patients with known hypersensitivity to any of its components.

  • WARNINGS

    FOR TOPICAL OPHTHALMIC USE. NOT FOR INJECTION INTO THE EYE. Sensitivity to topically applied aminoglycosides may occur in some patients. Severity of hypersensitivity reactions may vary from local effects to generalized reactions such as erythema, itching, urticaria, skin rash, anaphylaxis, anaphylactoid reactions, or bullous reactions. If a sensitivity reaction to tobramycin ophthalmic solution, USP 0.3% occurs, discontinue use.

  • PRECAUTIONS

    General

    As with other antibiotic preparations, prolonged use may result in overgrowth of nonsusceptible organisms, including fungi. If superinfection occurs, appropriate therapy should be initiated. Cross-sensitivity to other aminoglycoside antibiotics may occur; if hypersensitivity develops with this product, discontinue use and institute appropriate therapy. Patients should be advised not to wear contact lenses if they have signs and symptoms of bacterial conjunctivitis.

    Information for Patients

    Do not touch dropper tip to any surface, as this may contaminate the solution.

    Pregnancy

    Reproduction studies in 3 types of animals at doses up to 33 times the normal human systemic dose have revealed no evidence of impaired fertility or harm to the fetus due to tobramycin. There are, however, no adequate and well-controlled studies in pregnant women. Because animal studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.

    Nursing Mothers

    Because of the potential for adverse reactions in nursing infants from tobramycin ophthalmic solution, USP 0.3%, a decision should be made whether to discontinue nursing the infant or discontinue the drug, taking into account the importance of the drug to the mother.

    Pediatric Use

    Safety and effectiveness in pediatric patients below the age of 2 months has not been established.

    Geriatric Use

    No overall clinical differences in safety or effectiveness have been observed between elderly and younger patients.

  • ADVERSE REACTIONS

    The most frequent adverse reactions to tobramycin ophthalmic solution, USP 0.3% are hypersensitivity and localized ocular toxicity, including lid itching and swelling, and conjunctival erythema. These reactions occur in less than three of 100 patients treated with tobramycin ophthalmic solution, USP 0.3%.

    To report SUSPECTED ADVERSE REACTIONS, contact Sandoz Inc. at 1-800-525-8747 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

    Postmarketing Experience

    Additional adverse reactions identified from post-marketing use include anaphylactic reaction, Stevens-Johnson syndrome, and erythema multiforme.

  • DOSAGE AND ADMINISTRATION

    In mild to moderate disease, instill 1 or 2 drops into the affected eye(s) every 4 hours. In severe infections, instill 2 drops into the eye(s) hourly until improvement, following which treatment should be reduced prior to discontinuation.

  • HOW SUPPLIED

    Tobramycin ophthalmic solution, USP 0.3% is supplied as a 5 mL sterile solution, packaged in a 8 mL white plastic bottle with a plastic dispensing plug and white plastic closure as follows:

    5 mL containing tobramycin 0.3% (3 mg/mL)....... NDC 61314-643-05

    Storage

    Store at 2° to 25°C (36° to 77°F).

    After opening, tobramycin ophthalmic solution, USP 0.3% can be used until the expiration date on the bottle.

  • SPL UNCLASSIFIED SECTION

    Manufactured by Alcon Laboratories, Inc.
    Fort Worth, Texas 76134 for
    Sandoz Inc., Princeton, NJ 08540

    Revised: May 2020
    300037988-0520

  • PRINCIPAL DISPLAY PANEL

    NDC 61314-643-05

    Tobramycin
    Ophthalmic
    Solution, USP
    0.3%
    Rx only

    STERILE
    5 mL

    SANDOZ

    5mlcarton
  • INGREDIENTS AND APPEARANCE
    TOBRAMYCIN 
    tobramycin solution
    Product Information
    Product TypeHUMAN PRESCRIPTION DRUGItem Code (Source)NDC:61314-643
    Route of AdministrationOPHTHALMIC
    Active Ingredient/Active Moiety
    Ingredient NameBasis of StrengthStrength
    TOBRAMYCIN (UNII: VZ8RRZ51VK) (TOBRAMYCIN - UNII:VZ8RRZ51VK) TOBRAMYCIN3 mg  in 1 mL
    Inactive Ingredients
    Ingredient NameStrength
    BENZALKONIUM CHLORIDE (UNII: F5UM2KM3W7)  
    BORIC ACID (UNII: R57ZHV85D4)  
    SODIUM SULFATE (UNII: 0YPR65R21J)  
    SODIUM CHLORIDE (UNII: 451W47IQ8X)  
    TYLOXAPOL (UNII: Y27PUL9H56)  
    SODIUM HYDROXIDE (UNII: 55X04QC32I)  
    SULFURIC ACID (UNII: O40UQP6WCF)  
    WATER (UNII: 059QF0KO0R)  
    Packaging
    #Item CodePackage DescriptionMarketing Start DateMarketing End Date
    1NDC:61314-643-055 mL in 1 BOTTLE, PLASTIC; Type 0: Not a Combination Product01/09/1995
    Marketing Information
    Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
    ANDAANDA06253501/09/1995
    Labeler - Sandoz Inc (005387188)
    Registrant - Sandoz Inc (005387188)